Your session is about to expire
← Back to Search
Veliparib +/− Carboplatin for Breast Cancer
Study Summary
This trial looks at how well veliparib and carboplatin work to treat stage IV breast cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 509 Patients • NCT02163694Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can swallow pills without breaking or crushing them.I do not have severe health issues that are poorly controlled.I am a woman with advanced breast cancer that cannot be surgically removed and standard treatments are not effective.I cannot take platinum-based chemotherapy due to health reasons.My doctor expects me to live more than four months.Your liver enzymes (AST and ALT) must not be too high, unless you have evidence of cancer spread to the liver, in which case they can be a little higher.I haven't had seizures or needed steroids for my brain metastases for over 3 months.I finished my last chemotherapy for metastatic disease 3 weeks ago and any radiation or hormonal treatment 1 week ago.I am a woman aged 18 or older.I have had platinum-based or PARP inhibitor treatments, but it's been over a year since I last received them.My kidney function is normal or nearly normal.I am allergic to ABT-888 or similar medications.I haven't had cancer other than non-melanoma skin cancer or stage I ovarian cancer in the last 5 years.You have a disease that can be measured using specific criteria.I do not have an active severe infection or known HIV, hepatitis B, or hepatitis C.I can take care of myself and am up and about more than half of my waking hours.Your ANC (a type of white blood cell) count is at least 1,500 per microliter of blood.Your platelet count is at least 100,000 per microliter.I have brain metastases needing medication or causing symptoms.I have a confirmed harmful BRCA mutation from a certified lab.Your total bilirubin level should be within a certain range, not higher than 1.5 times the normal limit at the medical facility.
- Group 1: Safety Lead-In Phase (veliparib, carboplatin)
- Group 2: Phase II (veliparib, carboplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical facilities are hosting this clinical trial?
"Currently, this medical study is active in 23 sites. Among them are the University Health Network-Princess Margaret Hospital (Toronto), University of Chicago Comprehensive Cancer Centre (Chicago) and Penn State Milton S Hershey Medical Center (Hershey)."
How likely is it for individuals to suffer ill-effects from Veliparib?
"On a scale of one to three, our team assigned Veliparib a score of two due to the existing preliminary data on its safety but lack thereof pertaining to efficacy."
How many participants have signed up for this investigation?
"At this time, no further candidates are being recruited for the clinical trial. It was initially posted on June 30th 2010 and last updated July 27th 2022. Other opportunities are available however - 4558 studies recruiting participants with carcinoma and 716 trials enlisting patients to investigate Veliparib specifically."
Is there an opportunity for participants to enroll in this experiment?
"Unfortunately, clinicaltrials.gov reveals that this medical trial is no longer recruiting participants since it was first published on June 30th 2010 and last updated July 27th 2022. However, there are still 5274 other studies out there looking for new patients."
Are there any prior studies that have focused on Veliparib?
"Veliparib was initially explored in 2002 at H Central de Asturias and now, over a decade later, there have been 1406 completed studies. Currently, 716 separate experiments are ongoing within Toronto, Ontario."
Share this study with friends
Copy Link
Messenger